Mar 22, 2021
Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? In the United States, more than 2.5 million people are living with Epilepsy, out of which approximately 1 million continue to experience seizures despite adequate treatment with antiseizure drugs. Known as Drug-resistant epilep...
Read More...
Mar 19, 2021
Head and neck cancer account for about 4% of all cancers in the United States. According to GloboCan, the HNSCC incidence in the US in 2020 was estimated to be 63,520 cases. As per estimates, it was observed that HNSCC is slightly more common in men than in women. The research and development and advent of advanced...
Read More...
Mar 18, 2021
Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to younger patients, the company is reinforcing its pipeline with a pair of early-stage programs from Sanofi. In exchange for the global righ...
Read More...
Mar 17, 2021
Bleeding disorders, also known as coagulopathy, are a group of conditions in which the blood cannot clot properly due to the missing or defective protein. Bleeding Disorder can affect a person irrespective of his genders, ages and race and the person is likely to bleed more than the average person. A minor cut or s...
Read More...
Mar 16, 2021
Merck, Gilead to co-develop combined HIV treatments Merck and Gilead have announced a collaboration to investigate Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen. Both...
Read More...
Mar 15, 2021
An X-linked recessive disorder, Hemophilia occurs predominantly in males with females being the carriers. Patients diagnosed with Hemophilia usually lack one of the two proteins essential for the blood coagulation cascade namely factor VIII (FVIII) and factor IX (FIX). On the basis of the different blood coagulatio...
Read More...
Mar 12, 2021
More than 100 million people are living with one or the other form of Chronic Pain in the USA, says the Institute of Medicine. The available treatments to tackle cancer, as well as non-cancer pain, include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, or combinations of opioids and non-narc...
Read More...
Mar 11, 2021
Valo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster...
Read More...
Mar 10, 2021
Over the past few decades, the onset of technology has significantly improved the healthcare outcome for almost every section of society. Similarly, diagnostics, one of the critical segments of the healthcare system, have also been revamped remarkably. Earlier, even for a minor diagnostic test, the patient had to w...
Read More...
Mar 09, 2021
Gilead's Kite Receives Expanded Approval for its CAR-T Yescarta's in Follicular Lymphoma Gilead’s Kite has successfully secured success in launching the first-ever chimeric antigen receptor (CAR) T-cell therapy in the Follicular Lymphoma Market. The US FDA approved the Yescarta for adults with relapsed or ...
Read More...